WEBINAR - May 20, 2021:
Echocardiography for Aortic Stenosis in the TAVR Era
IAC (International Accreditation Commission)
WEBINAR with CEU Credit
Presenter: Enrique Garcia-Sayan, MD, FACC, FASE
Date: May 20, 2021
Time: 02:00 PM - 03:00 PM Eastern(11:00 AM - 12:00 PM Pacific)
Subject: Echocardiography for Aortic Stenosis in the TAVR Era
IAC Echocardiography will present a live webinar (followed by a Q&A session) entitled Echocardiography for Aortic Stenosis in the TAVR Era. This webinar is a joint presentation of IAC and ASE. In addition, registered participants will receive 1 contact hour of ASE CEU credit.
Repeated Mechanical Endovascular Thrombectomy for Recurrent Large Vessel Occlusion
29 April, 2021 - AHA Journal (American Heart Association)
Background and Purpose:
Mechanical thrombectomy (MT) is now the standard of care for large vessel occlusion (LVO) stroke. However, little is known about the frequency and outcomes of repeat MT (rMT) for patients with recurrent LVO.
Dual Antiplatelet Therapy Versus Aspirin in Patients With Stroke or Transient Ischemic Attack
27 April, 2021 - AHA Journal (American Heart Association)
Background and Purpose:
Antiplatelet therapy is key for preventing thrombotic events after transient ischemic attack or ischemic stroke. Although the role of aspirin is well established, there is emerging evidence for the role of short-term dual antiplatelet therapy (DAPT) in preventing recurrent stroke.;
Myocardial Histopathology in Patients with Obstructive Hypertrophic Cardiomyopathy
26 April, 2021 - JACC (Journal of the American College of Cardiology) Podcast
Hypertrophic cardiomyopathy (HCM) is characterized by multiple pathological features including myocyte hypertrophy, myocyte disarray, and interstitial fibrosis.
This study sought to correlate myocardial histopathology with clinical characteristics of patients with obstructive HCM and post-operative outcomes following septal myectomy.
Prospective ARNI vs. ACE inhibitor trial to Determine Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics
12 April, 2021 - NIH - National Library of Medicine
Aims: Patients surviving an acute myocardial infarction (AMI) are at risk of developing symptomatic heart failure (HF) or premature death. We hypothesized that sacubitril/valsartan, effective in the treatment of chronic HF, prevents the development of HF and reduces cardiovascular death following high-risk AMI compared to a proven angiotensin-converting enzyme (ACE) inhibitor. This paper describes the study design and baseline characteristics of patients enrolled in the Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI) trial.
Reducing Implicit Bias in the Admissions Process
Mayo Clinic College of Medicine & Science: Take 5 Video
A timely and helpful video reminder with a PDF checklist that we can use to reduce bias in our admissions processes.
Dr. Quinn Capers IV, an interventional cardiologist, medical educator, and Vice Dean for Faculty Affairs at The Ohio State University College of Medicine shares strategies his school's admissions office incorporated to recognize implicit bias and increase the diversity of healthcare teams.
DMS Cardiovascular news is a curated collection of articles, posts & studies related to general & interventional cardiology, cardiovascular & heart health that I found interesting and may be of help or interest to others. All articles are published on reliable and respected sources cited with links to read the original full article.